Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
How did NYXH's recent EPS compare to expectations?
The most recent EPS for Nyxoah SA is $-0.57, beating expectations of $-0.39.
How did Nyxoah SA NYXH's revenue perform in the last quarter?
Nyxoah SA revenue for the last quarter is $-0.57
What is the revenue estimate for Nyxoah SA?
According to 8 of Wall street analyst, the revenue estimate of Nyxoah SA range from $10.6M to $9.07M
What's the earning quality score for Nyxoah SA?
Nyxoah SA has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Nyxoah SA report earnings?
Nyxoah SA next earnings report is expected in 2026-11-03
What are Nyxoah SA's expected earnings?
Nyxoah SA expected earnings is $7.71M, according to wall-street analysts.
Did Nyxoah SA beat earnings expectations?
Nyxoah SA recent earnings of $7.72M beat expectations.